Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

S. Bajaj, Harpreet; M. Bergenstal, Richard; Christoffersen, Andreas; J. Davies, Melanie; Gowda, Amoolya; Isendahl, Joakim; Lingvay, Ildiko; Senior, Peter; Silver, Robert; Trevisan, Roberto; Rosenstock, Julio

doi:10.2337/dc20-2877

Public

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Published in Diabetes Care • Mar 19, 2021

Authors:

Harpreet S. Bajaj

Richard M. Bergenstal

Andreas Christoffersen

Abstract

OBJECTIVE Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowerin...

Subject

Medicine

Insulin glargine

Insulin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!